AskGene Pharma is a technology company.
AskGene Pharma has raised $20.0M across 1 funding round.
AskGene Pharma has raised $20.0M in total across 1 funding round.
AskGene Pharma has raised $20.0M in total across 1 funding round.
AskGene Pharma's investors include Qiming Venture Partners.
AskGene Pharma is a biotechnology company specializing in the discovery and development of novel antibody and fusion protein therapeutics, with a particular focus on next-generation cytokine prodrugs. Their proprietary SmartKine® cytokine prodrug platform enhances the developability and safety of cytokine therapies, targeting critical unmet medical needs in oncology, autoimmune diseases, and ophthalmology. AskGene serves patients and healthcare providers by developing safer, more effective treatments for cancers, inflammatory disorders, and eye diseases, advancing multiple candidates through preclinical and clinical stages with growing momentum supported by over $20 million in funding[1][2][5].
Founded in 2012 in Los Angeles, California, by a team of accomplished scientists from leading biotech organizations, AskGene emerged from a vision to overcome the limitations of existing cytokine therapeutics. Early milestones include rapid IND approval and phase 1 clinical trials starting in 2017, demonstrating strong early traction. The company has since evolved its focus to leverage its SmartKine® platform to create targeted cytokine fusion molecules that modulate immune responses selectively, addressing diseases such as gastric and colorectal cancers, lupus, inflammatory bowel disease, and diabetic macular edema[1][3][4][5].
AskGene is positioned at the forefront of the cytokine therapeutic trend, which aims to harness and modulate the immune system with greater precision and safety. The timing is critical as immunotherapies gain prominence in oncology and autoimmune disease treatment, but existing cytokines often suffer from toxicity and limited efficacy. AskGene’s prodrug approach addresses these challenges, aligning with market forces favoring personalized and safer biologics. By advancing next-generation cytokine therapies, AskGene influences the broader biotech ecosystem, encouraging innovation in immune modulation and expanding therapeutic options for difficult-to-treat diseases[1][2][5].
Looking ahead, AskGene Pharma is expected to continue advancing its clinical pipeline, potentially expanding indications and partnerships to accelerate commercialization. Trends such as precision immunotherapy, biologics innovation, and increasing demand for safer treatments will shape its trajectory. As the company matures, its influence may grow beyond cytokine therapeutics into broader immune-oncology and autoimmune disease markets, reinforcing its role as a leader in next-generation biologics. The SmartKine® platform’s success could redefine cytokine therapy standards, fulfilling AskGene’s mission to provide safer, better medicines that save lives[1][2][5].
AskGene Pharma has raised $20.0M across 1 funding round. Most recently, it raised $20.0M Series A in May 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2022 | $20.0M Series A | Qiming Venture Partners |